Clinical Trial Update: Efficacy and Safety of Sublingual Immunotherapy for Allergic Rhinitis Due to House Dust Mites [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sublingual immunotherapy for allergic rhinitis caused by house dust mites; the study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Sublingual immunotherapy for house dust mite (sublingual immunotherapy (HDM))

Snippet

Sponsor: Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | Conditions: Allergic Rhinitis Due to Dust Mite | Phase 2 | Status: NOT_YET_RECRUITING